BUZZ-Virpax Pharma declines after Nasdaq non-compliance notice** Shares of Virpax Pharmaceuticals VRPX.O fall 10.4% to 50 cents premarket
** Late on Friday, co disclosed it had received notice on Nov. 19 from Nasdaq about non-compliance with independent director and audit committee rules
** Co says it has appointed Esha Randhawa as an independent director and audit committee member; adds that it has regained compliance with listing rule
** Plans to notify Nasdaq of its compliance - VRPX
** As of last close, stock had fallen 82.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments